nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—BCL2—Paclitaxel—kidney cancer	0.541	0.879	CbGbCtD
Rasagiline—CYP1A2—Pazopanib—kidney cancer	0.0324	0.0527	CbGbCtD
Rasagiline—CYP1A2—Erlotinib—kidney cancer	0.0231	0.0376	CbGbCtD
Rasagiline—CYP1A2—Sorafenib—kidney cancer	0.0188	0.0305	CbGbCtD
Rasagiline—CYP1A2—urine—kidney cancer	0.00301	0.189	CbGeAlD
Rasagiline—BCL2—renal system—kidney cancer	0.00248	0.156	CbGeAlD
Rasagiline—BCL2—kidney—kidney cancer	0.0024	0.151	CbGeAlD
Rasagiline—BCL2—gonad—kidney cancer	0.00223	0.14	CbGeAlD
Rasagiline—MAOB—nephron tubule—kidney cancer	0.00114	0.0714	CbGeAlD
Rasagiline—MAOB—renal system—kidney cancer	0.00103	0.0649	CbGeAlD
Rasagiline—MAOB—kidney—kidney cancer	0.000999	0.0628	CbGeAlD
Rasagiline—MAOB—cortex of kidney—kidney cancer	0.000973	0.0611	CbGeAlD
Rasagiline—MAOB—cardiac atrium—kidney cancer	0.000926	0.0581	CbGeAlD
Rasagiline—CYP1A2—renal system—kidney cancer	0.000736	0.0462	CbGeAlD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—RAF1—kidney cancer	0.000164	0.00135	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—IL2—kidney cancer	0.000164	0.00134	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ACY1—kidney cancer	0.000163	0.00134	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—JUN—kidney cancer	0.000161	0.00132	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—MTOR—kidney cancer	0.00016	0.00131	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CTNNB1—kidney cancer	0.000158	0.00129	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—ERBB2—kidney cancer	0.000158	0.00129	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CUL7—kidney cancer	0.000155	0.00127	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—APC—kidney cancer	0.000153	0.00126	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CDKN1B—kidney cancer	0.00015	0.00123	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—BRAF—kidney cancer	0.000147	0.0012	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CDKN1B—kidney cancer	0.000146	0.0012	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CASP2—kidney cancer	0.000146	0.0012	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CDH1—kidney cancer	0.000144	0.00118	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—JUN—kidney cancer	0.000143	0.00117	CbGpPWpGaD
Rasagiline—BCL2—Immune System—SRMS—kidney cancer	0.000142	0.00116	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—KDR—kidney cancer	0.000141	0.00116	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CDH1—kidney cancer	0.000141	0.00116	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CCND1—kidney cancer	0.000139	0.00114	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—JUN—kidney cancer	0.000139	0.00114	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PDHB—kidney cancer	0.000138	0.00114	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—PTEN—kidney cancer	0.000138	0.00113	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—MET—kidney cancer	0.000138	0.00113	CbGpPWpGaD
Rasagiline—MAOB—Biological oxidations—POMC—kidney cancer	0.000138	0.00113	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CTNNB1—kidney cancer	0.000138	0.00113	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—MYC—kidney cancer	0.000138	0.00113	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—MYC—kidney cancer	0.000138	0.00113	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PTEN—kidney cancer	0.000134	0.0011	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CARD11—kidney cancer	0.000133	0.00109	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—MAPK3—kidney cancer	0.000133	0.00109	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—MAPK3—kidney cancer	0.000131	0.00108	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CCBL1—kidney cancer	0.00013	0.00107	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	0.00013	0.00106	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—KRAS—kidney cancer	0.000127	0.00104	CbGpPWpGaD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.000125	0.00103	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—MAPK1—kidney cancer	0.000125	0.00103	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—ITPR2—kidney cancer	0.000124	0.00102	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—kidney cancer	0.000123	0.00101	CbGpPWpGaD
Rasagiline—CYP1A2—Tryptophan metabolism—CYP1A1—kidney cancer	0.000123	0.00101	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—kidney cancer	0.000123	0.00101	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—BRAF—kidney cancer	0.000122	0.001	CbGpPWpGaD
Rasagiline—CYP1A2—Phase II conjugation—GSTT1—kidney cancer	0.000121	0.000994	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—ALDH1A1—kidney cancer	0.000121	0.00099	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MTOR—kidney cancer	0.00012	0.000982	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD274—kidney cancer	0.000118	0.000963	CbGpPWpGaD
Rasagiline—CYP1A2—Arachidonic acid metabolism—CYP1A1—kidney cancer	0.000115	0.000944	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—JUN—kidney cancer	0.000114	0.000932	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—kidney cancer	0.000113	0.000926	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PPAT—kidney cancer	0.000113	0.000925	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GLIPR1—kidney cancer	0.000113	0.000925	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—MAPK1—kidney cancer	0.000113	0.000923	CbGpPWpGaD
Rasagiline—BCL2—Immune System—VHL—kidney cancer	0.000112	0.000919	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—MYC—kidney cancer	0.000112	0.000915	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—PTEN—kidney cancer	0.00011	0.000902	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—MAPK1—kidney cancer	0.000109	0.000895	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CTSB—kidney cancer	0.000108	0.000882	CbGpPWpGaD
Rasagiline—BCL2—Immune System—TXNIP—kidney cancer	0.000107	0.000881	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CCND1—kidney cancer	0.000107	0.000879	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—JUN—kidney cancer	0.000107	0.000877	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CTNNB1—kidney cancer	0.000106	0.000871	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TP53—kidney cancer	0.000106	0.000868	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—FH—kidney cancer	0.000105	0.00086	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—APRT—kidney cancer	0.000105	0.00086	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CTNNB1—kidney cancer	0.000104	0.000853	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—PTEN—kidney cancer	0.000104	0.000849	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—KRAS—kidney cancer	0.000103	0.000846	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—RAF1—kidney cancer	0.000102	0.000837	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	0.000102	0.000834	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—ERBB2—kidney cancer	0.000101	0.000828	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	0.000101	0.000825	CbGpPWpGaD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	9.95e-05	0.000816	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GPC3—kidney cancer	9.87e-05	0.000809	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	9.84e-05	0.000806	CbGpPWpGaD
Rasagiline—BCL2—Immune System—TCEB2—kidney cancer	9.83e-05	0.000806	CbGpPWpGaD
Rasagiline—BCL2—Immune System—TCEB1—kidney cancer	9.83e-05	0.000806	CbGpPWpGaD
Rasagiline—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	9.82e-05	0.000805	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CA2—kidney cancer	9.6e-05	0.000787	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PIK3CA—kidney cancer	9.48e-05	0.000777	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TP53—kidney cancer	9.45e-05	0.000775	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KEAP1—kidney cancer	9.4e-05	0.00077	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ALAD—kidney cancer	9.35e-05	0.000767	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—VEGFA—kidney cancer	9.35e-05	0.000767	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PAK1—kidney cancer	9.33e-05	0.000765	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	9.32e-05	0.000764	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TP53—kidney cancer	9.17e-05	0.000752	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ST3GAL2—kidney cancer	9.13e-05	0.000748	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IFNA1—kidney cancer	9.1e-05	0.000746	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—CCND1—kidney cancer	8.93e-05	0.000732	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ALDH1A1—kidney cancer	8.92e-05	0.000731	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—JUN—kidney cancer	8.91e-05	0.00073	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	8.89e-05	0.000729	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	8.87e-05	0.000727	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—CTNNB1—kidney cancer	8.84e-05	0.000725	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	8.8e-05	0.000721	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PTEN—kidney cancer	8.61e-05	0.000706	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MYC—kidney cancer	8.6e-05	0.000705	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	8.58e-05	0.000703	CbGpPWpGaD
Rasagiline—Osteoarthritis—Doxorubicin—kidney cancer	8.56e-05	0.000347	CcSEcCtD
Rasagiline—MAOB—Metabolism—SLC5A3—kidney cancer	8.56e-05	0.000701	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PGK1—kidney cancer	8.56e-05	0.000701	CbGpPWpGaD
Rasagiline—Paraesthesia—Gemcitabine—kidney cancer	8.53e-05	0.000345	CcSEcCtD
Rasagiline—Cardiac disorder—Capecitabine—kidney cancer	8.53e-05	0.000345	CcSEcCtD
Rasagiline—Cough—Paclitaxel—kidney cancer	8.5e-05	0.000344	CcSEcCtD
Rasagiline—BCL2—Immune System—CASP2—kidney cancer	8.5e-05	0.000697	CbGpPWpGaD
Rasagiline—Asthenia—Sunitinib—kidney cancer	8.49e-05	0.000344	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—IFNA2—kidney cancer	8.47e-05	0.000695	CbGpPWpGaD
Rasagiline—Dyspnoea—Gemcitabine—kidney cancer	8.47e-05	0.000343	CcSEcCtD
Rasagiline—Nausea—Vinblastine—kidney cancer	8.45e-05	0.000342	CcSEcCtD
Rasagiline—Somnolence—Gemcitabine—kidney cancer	8.45e-05	0.000342	CcSEcCtD
Rasagiline—Convulsion—Paclitaxel—kidney cancer	8.44e-05	0.000342	CcSEcCtD
Rasagiline—Affect lability—Doxorubicin—kidney cancer	8.43e-05	0.000341	CcSEcCtD
Rasagiline—Migraine—Doxorubicin—kidney cancer	8.43e-05	0.000341	CcSEcCtD
Rasagiline—Nausea—Everolimus—kidney cancer	8.42e-05	0.000341	CcSEcCtD
Rasagiline—Diarrhoea—Sorafenib—kidney cancer	8.42e-05	0.000341	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MAPK1—kidney cancer	8.42e-05	0.00069	CbGpPWpGaD
Rasagiline—Hypertension—Paclitaxel—kidney cancer	8.41e-05	0.000341	CcSEcCtD
Rasagiline—CYP1A2—Phase II conjugation—GSTP1—kidney cancer	8.41e-05	0.000689	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—LDHB—kidney cancer	8.39e-05	0.000688	CbGpPWpGaD
Rasagiline—Pruritus—Sunitinib—kidney cancer	8.38e-05	0.000339	CcSEcCtD
Rasagiline—Angiopathy—Capecitabine—kidney cancer	8.34e-05	0.000338	CcSEcCtD
Rasagiline—Immune system disorder—Capecitabine—kidney cancer	8.3e-05	0.000336	CcSEcCtD
Rasagiline—Chest pain—Paclitaxel—kidney cancer	8.3e-05	0.000336	CcSEcCtD
Rasagiline—Arthralgia—Paclitaxel—kidney cancer	8.3e-05	0.000336	CcSEcCtD
Rasagiline—Mediastinal disorder—Capecitabine—kidney cancer	8.28e-05	0.000335	CcSEcCtD
Rasagiline—Anxiety—Paclitaxel—kidney cancer	8.27e-05	0.000335	CcSEcCtD
Rasagiline—Face oedema—Doxorubicin—kidney cancer	8.26e-05	0.000335	CcSEcCtD
Rasagiline—Decreased appetite—Gemcitabine—kidney cancer	8.26e-05	0.000334	CcSEcCtD
Rasagiline—Hypersensitivity—Dactinomycin—kidney cancer	8.26e-05	0.000334	CcSEcCtD
Rasagiline—Chills—Capecitabine—kidney cancer	8.24e-05	0.000334	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	8.24e-05	0.000334	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Gemcitabine—kidney cancer	8.2e-05	0.000332	CcSEcCtD
Rasagiline—Discomfort—Paclitaxel—kidney cancer	8.2e-05	0.000332	CcSEcCtD
Rasagiline—Gastrointestinal pain—Vincristine—kidney cancer	8.19e-05	0.000332	CcSEcCtD
Rasagiline—BCL2—Immune System—CD34—kidney cancer	8.15e-05	0.000668	CbGpPWpGaD
Rasagiline—Dizziness—Sorafenib—kidney cancer	8.14e-05	0.000329	CcSEcCtD
Rasagiline—Constipation—Gemcitabine—kidney cancer	8.12e-05	0.000329	CcSEcCtD
Rasagiline—Nausea—Erlotinib—kidney cancer	8.12e-05	0.000329	CcSEcCtD
Rasagiline—Alopecia—Capecitabine—kidney cancer	8.12e-05	0.000329	CcSEcCtD
Rasagiline—Dry mouth—Paclitaxel—kidney cancer	8.11e-05	0.000329	CcSEcCtD
Rasagiline—Mood swings—Doxorubicin—kidney cancer	8.11e-05	0.000328	CcSEcCtD
Rasagiline—Diarrhoea—Sunitinib—kidney cancer	8.1e-05	0.000328	CcSEcCtD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	8.07e-05	0.000661	CbGpPWpGaD
Rasagiline—Ataxia—Doxorubicin—kidney cancer	8.05e-05	0.000326	CcSEcCtD
Rasagiline—Mental disorder—Capecitabine—kidney cancer	8.05e-05	0.000326	CcSEcCtD
Rasagiline—Asthenia—Dactinomycin—kidney cancer	8.04e-05	0.000326	CcSEcCtD
Rasagiline—Confusional state—Paclitaxel—kidney cancer	8.02e-05	0.000325	CcSEcCtD
Rasagiline—Malnutrition—Capecitabine—kidney cancer	8e-05	0.000324	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—KRAS—kidney cancer	7.95e-05	0.000652	CbGpPWpGaD
Rasagiline—Body temperature increased—Vincristine—kidney cancer	7.92e-05	0.000321	CcSEcCtD
Rasagiline—Abdominal pain—Vincristine—kidney cancer	7.92e-05	0.000321	CcSEcCtD
Rasagiline—Liver function test abnormal—Doxorubicin—kidney cancer	7.9e-05	0.00032	CcSEcCtD
Rasagiline—Infection—Paclitaxel—kidney cancer	7.9e-05	0.00032	CcSEcCtD
Rasagiline—Flatulence—Capecitabine—kidney cancer	7.88e-05	0.000319	CcSEcCtD
Rasagiline—Dysgeusia—Capecitabine—kidney cancer	7.83e-05	0.000317	CcSEcCtD
Rasagiline—Dizziness—Sunitinib—kidney cancer	7.83e-05	0.000317	CcSEcCtD
Rasagiline—Feeling abnormal—Gemcitabine—kidney cancer	7.83e-05	0.000317	CcSEcCtD
Rasagiline—Shock—Paclitaxel—kidney cancer	7.83e-05	0.000317	CcSEcCtD
Rasagiline—Vomiting—Sorafenib—kidney cancer	7.82e-05	0.000317	CcSEcCtD
Rasagiline—Orthostatic hypotension—Doxorubicin—kidney cancer	7.82e-05	0.000317	CcSEcCtD
Rasagiline—Nervous system disorder—Paclitaxel—kidney cancer	7.8e-05	0.000316	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—VEGFA—kidney cancer	7.78e-05	0.000638	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CARD11—kidney cancer	7.77e-05	0.000637	CbGpPWpGaD
Rasagiline—Rash—Sorafenib—kidney cancer	7.76e-05	0.000314	CcSEcCtD
Rasagiline—Dermatitis—Sorafenib—kidney cancer	7.75e-05	0.000314	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	7.75e-05	0.000635	CbGpPWpGaD
Rasagiline—Back pain—Capecitabine—kidney cancer	7.74e-05	0.000313	CcSEcCtD
Rasagiline—CYP1A2—Phase II conjugation—GSTM1—kidney cancer	7.73e-05	0.000633	CbGpPWpGaD
Rasagiline—Skin disorder—Paclitaxel—kidney cancer	7.73e-05	0.000313	CcSEcCtD
Rasagiline—Headache—Sorafenib—kidney cancer	7.71e-05	0.000312	CcSEcCtD
Rasagiline—Muscle spasms—Capecitabine—kidney cancer	7.69e-05	0.000311	CcSEcCtD
Rasagiline—Hyperhidrosis—Paclitaxel—kidney cancer	7.69e-05	0.000311	CcSEcCtD
Rasagiline—Diarrhoea—Dactinomycin—kidney cancer	7.67e-05	0.000311	CcSEcCtD
Rasagiline—Anorexia—Paclitaxel—kidney cancer	7.58e-05	0.000307	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—kidney cancer	7.57e-05	0.00062	CbGpPWpGaD
Rasagiline—Muscular weakness—Doxorubicin—kidney cancer	7.55e-05	0.000306	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—RELA—kidney cancer	7.53e-05	0.000617	CbGpPWpGaD
Rasagiline—Vomiting—Sunitinib—kidney cancer	7.53e-05	0.000305	CcSEcCtD
Rasagiline—Body temperature increased—Gemcitabine—kidney cancer	7.51e-05	0.000304	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—TP53—kidney cancer	7.51e-05	0.000615	CbGpPWpGaD
Rasagiline—Tremor—Capecitabine—kidney cancer	7.49e-05	0.000303	CcSEcCtD
Rasagiline—Rash—Sunitinib—kidney cancer	7.47e-05	0.000302	CcSEcCtD
Rasagiline—Dermatitis—Sunitinib—kidney cancer	7.46e-05	0.000302	CcSEcCtD
Rasagiline—Hypotension—Paclitaxel—kidney cancer	7.43e-05	0.000301	CcSEcCtD
Rasagiline—Ill-defined disorder—Capecitabine—kidney cancer	7.42e-05	0.0003	CcSEcCtD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	7.42e-05	0.000608	CbGpPWpGaD
Rasagiline—Headache—Sunitinib—kidney cancer	7.42e-05	0.0003	CcSEcCtD
Rasagiline—Dysphagia—Doxorubicin—kidney cancer	7.4e-05	0.0003	CcSEcCtD
Rasagiline—Influenza—Doxorubicin—kidney cancer	7.4e-05	0.0003	CcSEcCtD
Rasagiline—Asthma—Doxorubicin—kidney cancer	7.4e-05	0.0003	CcSEcCtD
Rasagiline—Anaemia—Capecitabine—kidney cancer	7.39e-05	0.000299	CcSEcCtD
Rasagiline—Hypersensitivity—Vincristine—kidney cancer	7.38e-05	0.000299	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	7.33e-05	0.000601	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—kidney cancer	7.32e-05	0.0006	CbGpPWpGaD
Rasagiline—Nausea—Sorafenib—kidney cancer	7.31e-05	0.000296	CcSEcCtD
Rasagiline—MAOB—Metabolism—CA9—kidney cancer	7.27e-05	0.000596	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Paclitaxel—kidney cancer	7.25e-05	0.000293	CcSEcCtD
Rasagiline—BCL2—Immune System—ITPR2—kidney cancer	7.22e-05	0.000592	CbGpPWpGaD
Rasagiline—Malaise—Capecitabine—kidney cancer	7.21e-05	0.000292	CcSEcCtD
Rasagiline—Angina pectoris—Doxorubicin—kidney cancer	7.21e-05	0.000292	CcSEcCtD
Rasagiline—Insomnia—Paclitaxel—kidney cancer	7.19e-05	0.000291	CcSEcCtD
Rasagiline—Vertigo—Capecitabine—kidney cancer	7.19e-05	0.000291	CcSEcCtD
Rasagiline—Asthenia—Vincristine—kidney cancer	7.18e-05	0.000291	CcSEcCtD
Rasagiline—Syncope—Capecitabine—kidney cancer	7.17e-05	0.00029	CcSEcCtD
Rasagiline—Leukopenia—Capecitabine—kidney cancer	7.16e-05	0.00029	CcSEcCtD
Rasagiline—Paraesthesia—Paclitaxel—kidney cancer	7.14e-05	0.000289	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	7.13e-05	0.000584	CbGpPWpGaD
Rasagiline—Vomiting—Dactinomycin—kidney cancer	7.13e-05	0.000289	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—GSTT1—kidney cancer	7.1e-05	0.000582	CbGpPWpGaD
Rasagiline—Dyspnoea—Paclitaxel—kidney cancer	7.09e-05	0.000287	CcSEcCtD
Rasagiline—Somnolence—Paclitaxel—kidney cancer	7.07e-05	0.000286	CcSEcCtD
Rasagiline—Rash—Dactinomycin—kidney cancer	7.07e-05	0.000286	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TP53—kidney cancer	7.07e-05	0.000579	CbGpPWpGaD
Rasagiline—Nausea—Sunitinib—kidney cancer	7.03e-05	0.000285	CcSEcCtD
Rasagiline—Loss of consciousness—Capecitabine—kidney cancer	7.03e-05	0.000285	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—MAPK1—kidney cancer	7e-05	0.000574	CbGpPWpGaD
Rasagiline—Dyspepsia—Paclitaxel—kidney cancer	7e-05	0.000283	CcSEcCtD
Rasagiline—Cough—Capecitabine—kidney cancer	6.98e-05	0.000283	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	6.97e-05	0.000572	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—kidney cancer	6.93e-05	0.000568	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—kidney cancer	6.93e-05	0.000568	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—kidney cancer	6.92e-05	0.000567	CbGpPWpGaD
Rasagiline—Dysuria—Doxorubicin—kidney cancer	6.92e-05	0.00028	CcSEcCtD
Rasagiline—Decreased appetite—Paclitaxel—kidney cancer	6.91e-05	0.00028	CcSEcCtD
Rasagiline—Hypertension—Capecitabine—kidney cancer	6.9e-05	0.00028	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Doxorubicin—kidney cancer	6.88e-05	0.000278	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Paclitaxel—kidney cancer	6.87e-05	0.000278	CcSEcCtD
Rasagiline—Diarrhoea—Vincristine—kidney cancer	6.85e-05	0.000277	CcSEcCtD
Rasagiline—CYP1A2—Arachidonic acid metabolism—PTGS2—kidney cancer	6.85e-05	0.000561	CbGpPWpGaD
Rasagiline—Pollakiuria—Doxorubicin—kidney cancer	6.83e-05	0.000277	CcSEcCtD
Rasagiline—Asthenia—Gemcitabine—kidney cancer	6.82e-05	0.000276	CcSEcCtD
Rasagiline—Chest pain—Capecitabine—kidney cancer	6.81e-05	0.000276	CcSEcCtD
Rasagiline—Arthralgia—Capecitabine—kidney cancer	6.81e-05	0.000276	CcSEcCtD
Rasagiline—Constipation—Paclitaxel—kidney cancer	6.8e-05	0.000275	CcSEcCtD
Rasagiline—Anxiety—Capecitabine—kidney cancer	6.79e-05	0.000275	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—kidney cancer	6.78e-05	0.000556	CbGpPWpGaD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	6.76e-05	0.000274	CcSEcCtD
Rasagiline—Photosensitivity reaction—Doxorubicin—kidney cancer	6.75e-05	0.000273	CcSEcCtD
Rasagiline—Discomfort—Capecitabine—kidney cancer	6.73e-05	0.000272	CcSEcCtD
Rasagiline—Pruritus—Gemcitabine—kidney cancer	6.72e-05	0.000272	CcSEcCtD
Rasagiline—Weight decreased—Doxorubicin—kidney cancer	6.69e-05	0.000271	CcSEcCtD
Rasagiline—Dry mouth—Capecitabine—kidney cancer	6.66e-05	0.00027	CcSEcCtD
Rasagiline—Nausea—Dactinomycin—kidney cancer	6.66e-05	0.00027	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—PTGS1—kidney cancer	6.65e-05	0.000545	CbGpPWpGaD
Rasagiline—Dizziness—Vincristine—kidney cancer	6.62e-05	0.000268	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—kidney cancer	6.6e-05	0.000541	CbGpPWpGaD
Rasagiline—Infestation NOS—Doxorubicin—kidney cancer	6.6e-05	0.000267	CcSEcCtD
Rasagiline—Infestation—Doxorubicin—kidney cancer	6.6e-05	0.000267	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	6.59e-05	0.00054	CbGpPWpGaD
Rasagiline—Confusional state—Capecitabine—kidney cancer	6.58e-05	0.000266	CcSEcCtD
Rasagiline—Feeling abnormal—Paclitaxel—kidney cancer	6.55e-05	0.000265	CcSEcCtD
Rasagiline—Gastrointestinal pain—Paclitaxel—kidney cancer	6.5e-05	0.000263	CcSEcCtD
Rasagiline—Diarrhoea—Gemcitabine—kidney cancer	6.5e-05	0.000263	CcSEcCtD
Rasagiline—Infection—Capecitabine—kidney cancer	6.48e-05	0.000263	CcSEcCtD
Rasagiline—Neuropathy peripheral—Doxorubicin—kidney cancer	6.47e-05	0.000262	CcSEcCtD
Rasagiline—Stomatitis—Doxorubicin—kidney cancer	6.43e-05	0.00026	CcSEcCtD
Rasagiline—Jaundice—Doxorubicin—kidney cancer	6.43e-05	0.00026	CcSEcCtD
Rasagiline—Shock—Capecitabine—kidney cancer	6.42e-05	0.00026	CcSEcCtD
Rasagiline—Conjunctivitis—Doxorubicin—kidney cancer	6.41e-05	0.00026	CcSEcCtD
Rasagiline—Nervous system disorder—Capecitabine—kidney cancer	6.4e-05	0.000259	CcSEcCtD
Rasagiline—Vomiting—Vincristine—kidney cancer	6.37e-05	0.000258	CcSEcCtD
Rasagiline—Skin disorder—Capecitabine—kidney cancer	6.34e-05	0.000257	CcSEcCtD
Rasagiline—Sweating—Doxorubicin—kidney cancer	6.32e-05	0.000256	CcSEcCtD
Rasagiline—Urticaria—Paclitaxel—kidney cancer	6.32e-05	0.000256	CcSEcCtD
Rasagiline—Rash—Vincristine—kidney cancer	6.31e-05	0.000256	CcSEcCtD
Rasagiline—Hyperhidrosis—Capecitabine—kidney cancer	6.31e-05	0.000255	CcSEcCtD
Rasagiline—Dermatitis—Vincristine—kidney cancer	6.31e-05	0.000255	CcSEcCtD
Rasagiline—Haematuria—Doxorubicin—kidney cancer	6.29e-05	0.000255	CcSEcCtD
Rasagiline—Abdominal pain—Paclitaxel—kidney cancer	6.29e-05	0.000255	CcSEcCtD
Rasagiline—Body temperature increased—Paclitaxel—kidney cancer	6.29e-05	0.000255	CcSEcCtD
Rasagiline—Headache—Vincristine—kidney cancer	6.27e-05	0.000254	CcSEcCtD
Rasagiline—BCL2—Immune System—CTSB—kidney cancer	6.27e-05	0.000514	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CTSD—kidney cancer	6.24e-05	0.000511	CbGpPWpGaD
Rasagiline—Epistaxis—Doxorubicin—kidney cancer	6.22e-05	0.000252	CcSEcCtD
Rasagiline—Anorexia—Capecitabine—kidney cancer	6.22e-05	0.000252	CcSEcCtD
Rasagiline—MAOB—Metabolism—CRABP1—kidney cancer	6.19e-05	0.000507	CbGpPWpGaD
Rasagiline—Hypotension—Capecitabine—kidney cancer	6.1e-05	0.000247	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—PIK3CA—kidney cancer	6.08e-05	0.000498	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—TSC2—kidney cancer	6.06e-05	0.000497	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PSMD7—kidney cancer	6.05e-05	0.000496	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	6.05e-05	0.000496	CbGpPWpGaD
Rasagiline—Vomiting—Gemcitabine—kidney cancer	6.04e-05	0.000245	CcSEcCtD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—POMC—kidney cancer	6.01e-05	0.000493	CbGpPWpGaD
Rasagiline—Rash—Gemcitabine—kidney cancer	5.99e-05	0.000243	CcSEcCtD
Rasagiline—Dermatitis—Gemcitabine—kidney cancer	5.98e-05	0.000242	CcSEcCtD
Rasagiline—Haemoglobin—Doxorubicin—kidney cancer	5.95e-05	0.000241	CcSEcCtD
Rasagiline—Headache—Gemcitabine—kidney cancer	5.95e-05	0.000241	CcSEcCtD
Rasagiline—Nausea—Vincristine—kidney cancer	5.95e-05	0.000241	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Capecitabine—kidney cancer	5.95e-05	0.000241	CcSEcCtD
Rasagiline—Rhinitis—Doxorubicin—kidney cancer	5.94e-05	0.00024	CcSEcCtD
Rasagiline—Haemorrhage—Doxorubicin—kidney cancer	5.92e-05	0.00024	CcSEcCtD
Rasagiline—Insomnia—Capecitabine—kidney cancer	5.9e-05	0.000239	CcSEcCtD
Rasagiline—Hypoaesthesia—Doxorubicin—kidney cancer	5.89e-05	0.000239	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	5.87e-05	0.000481	CbGpPWpGaD
Rasagiline—Paraesthesia—Capecitabine—kidney cancer	5.86e-05	0.000237	CcSEcCtD
Rasagiline—Hypersensitivity—Paclitaxel—kidney cancer	5.86e-05	0.000237	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	5.85e-05	0.00048	CbGpPWpGaD
Rasagiline—Urinary tract disorder—Doxorubicin—kidney cancer	5.85e-05	0.000237	CcSEcCtD
Rasagiline—Oedema peripheral—Doxorubicin—kidney cancer	5.83e-05	0.000236	CcSEcCtD
Rasagiline—Connective tissue disorder—Doxorubicin—kidney cancer	5.82e-05	0.000236	CcSEcCtD
Rasagiline—Dyspnoea—Capecitabine—kidney cancer	5.82e-05	0.000236	CcSEcCtD
Rasagiline—Urethral disorder—Doxorubicin—kidney cancer	5.81e-05	0.000235	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—kidney cancer	5.77e-05	0.000473	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ITPR2—kidney cancer	5.75e-05	0.000471	CbGpPWpGaD
Rasagiline—Dyspepsia—Capecitabine—kidney cancer	5.75e-05	0.000233	CcSEcCtD
Rasagiline—Asthenia—Paclitaxel—kidney cancer	5.71e-05	0.000231	CcSEcCtD
Rasagiline—Decreased appetite—Capecitabine—kidney cancer	5.67e-05	0.00023	CcSEcCtD
Rasagiline—Nausea—Gemcitabine—kidney cancer	5.64e-05	0.000228	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Capecitabine—kidney cancer	5.64e-05	0.000228	CcSEcCtD
Rasagiline—Pruritus—Paclitaxel—kidney cancer	5.63e-05	0.000228	CcSEcCtD
Rasagiline—Constipation—Capecitabine—kidney cancer	5.58e-05	0.000226	CcSEcCtD
Rasagiline—Eye disorder—Doxorubicin—kidney cancer	5.53e-05	0.000224	CcSEcCtD
Rasagiline—Cardiac disorder—Doxorubicin—kidney cancer	5.5e-05	0.000223	CcSEcCtD
Rasagiline—Diarrhoea—Paclitaxel—kidney cancer	5.44e-05	0.00022	CcSEcCtD
Rasagiline—BCL2—Immune System—PAK1—kidney cancer	5.44e-05	0.000446	CbGpPWpGaD
Rasagiline—Feeling abnormal—Capecitabine—kidney cancer	5.38e-05	0.000218	CcSEcCtD
Rasagiline—Angiopathy—Doxorubicin—kidney cancer	5.37e-05	0.000218	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—KIT—kidney cancer	5.35e-05	0.000439	CbGpPWpGaD
Rasagiline—Immune system disorder—Doxorubicin—kidney cancer	5.35e-05	0.000217	CcSEcCtD
Rasagiline—Gastrointestinal pain—Capecitabine—kidney cancer	5.34e-05	0.000216	CcSEcCtD
Rasagiline—Mediastinal disorder—Doxorubicin—kidney cancer	5.34e-05	0.000216	CcSEcCtD
Rasagiline—Chills—Doxorubicin—kidney cancer	5.31e-05	0.000215	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—MYC—kidney cancer	5.3e-05	0.000435	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNA1—kidney cancer	5.3e-05	0.000435	CbGpPWpGaD
Rasagiline—Dizziness—Paclitaxel—kidney cancer	5.26e-05	0.000213	CcSEcCtD
Rasagiline—MAOB—Metabolism—ACHE—kidney cancer	5.24e-05	0.00043	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTT1—kidney cancer	5.24e-05	0.00043	CbGpPWpGaD
Rasagiline—Alopecia—Doxorubicin—kidney cancer	5.23e-05	0.000212	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—kidney cancer	5.19e-05	0.000425	CbGpPWpGaD
Rasagiline—Mental disorder—Doxorubicin—kidney cancer	5.19e-05	0.00021	CcSEcCtD
Rasagiline—Urticaria—Capecitabine—kidney cancer	5.19e-05	0.00021	CcSEcCtD
Rasagiline—Abdominal pain—Capecitabine—kidney cancer	5.16e-05	0.000209	CcSEcCtD
Rasagiline—Body temperature increased—Capecitabine—kidney cancer	5.16e-05	0.000209	CcSEcCtD
Rasagiline—Malnutrition—Doxorubicin—kidney cancer	5.16e-05	0.000209	CcSEcCtD
Rasagiline—BCL2—Immune System—EGR1—kidney cancer	5.08e-05	0.000417	CbGpPWpGaD
Rasagiline—Flatulence—Doxorubicin—kidney cancer	5.08e-05	0.000206	CcSEcCtD
Rasagiline—Vomiting—Paclitaxel—kidney cancer	5.06e-05	0.000205	CcSEcCtD
Rasagiline—Dysgeusia—Doxorubicin—kidney cancer	5.05e-05	0.000204	CcSEcCtD
Rasagiline—Rash—Paclitaxel—kidney cancer	5.02e-05	0.000203	CcSEcCtD
Rasagiline—Dermatitis—Paclitaxel—kidney cancer	5.01e-05	0.000203	CcSEcCtD
Rasagiline—Back pain—Doxorubicin—kidney cancer	4.99e-05	0.000202	CcSEcCtD
Rasagiline—Headache—Paclitaxel—kidney cancer	4.98e-05	0.000202	CcSEcCtD
Rasagiline—MAOB—Metabolism—SCARB1—kidney cancer	4.96e-05	0.000407	CbGpPWpGaD
Rasagiline—Muscle spasms—Doxorubicin—kidney cancer	4.96e-05	0.000201	CcSEcCtD
Rasagiline—BCL2—Immune System—IFNA2—kidney cancer	4.94e-05	0.000405	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—GSTP1—kidney cancer	4.92e-05	0.000403	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTGS1—kidney cancer	4.91e-05	0.000403	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—kidney cancer	4.9e-05	0.000402	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTP1—kidney cancer	4.85e-05	0.000398	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PSMD7—kidney cancer	4.82e-05	0.000395	CbGpPWpGaD
Rasagiline—Hypersensitivity—Capecitabine—kidney cancer	4.81e-05	0.000195	CcSEcCtD
Rasagiline—Ill-defined disorder—Doxorubicin—kidney cancer	4.78e-05	0.000194	CcSEcCtD
Rasagiline—Anaemia—Doxorubicin—kidney cancer	4.76e-05	0.000193	CcSEcCtD
Rasagiline—Agitation—Doxorubicin—kidney cancer	4.74e-05	0.000192	CcSEcCtD
Rasagiline—Nausea—Paclitaxel—kidney cancer	4.72e-05	0.000191	CcSEcCtD
Rasagiline—Asthenia—Capecitabine—kidney cancer	4.68e-05	0.00019	CcSEcCtD
Rasagiline—Malaise—Doxorubicin—kidney cancer	4.65e-05	0.000188	CcSEcCtD
Rasagiline—Vertigo—Doxorubicin—kidney cancer	4.63e-05	0.000188	CcSEcCtD
Rasagiline—Syncope—Doxorubicin—kidney cancer	4.62e-05	0.000187	CcSEcCtD
Rasagiline—Pruritus—Capecitabine—kidney cancer	4.62e-05	0.000187	CcSEcCtD
Rasagiline—Leukopenia—Doxorubicin—kidney cancer	4.61e-05	0.000187	CcSEcCtD
Rasagiline—MAOB—Metabolism—BCHE—kidney cancer	4.57e-05	0.000374	CbGpPWpGaD
Rasagiline—Loss of consciousness—Doxorubicin—kidney cancer	4.53e-05	0.000183	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—GSTM1—kidney cancer	4.52e-05	0.000371	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—SLC5A5—kidney cancer	4.51e-05	0.00037	CbGpPWpGaD
Rasagiline—Cough—Doxorubicin—kidney cancer	4.5e-05	0.000182	CcSEcCtD
Rasagiline—Convulsion—Doxorubicin—kidney cancer	4.47e-05	0.000181	CcSEcCtD
Rasagiline—Diarrhoea—Capecitabine—kidney cancer	4.47e-05	0.000181	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTM1—kidney cancer	4.46e-05	0.000365	CbGpPWpGaD
Rasagiline—Hypertension—Doxorubicin—kidney cancer	4.45e-05	0.00018	CcSEcCtD
Rasagiline—Arthralgia—Doxorubicin—kidney cancer	4.39e-05	0.000178	CcSEcCtD
Rasagiline—Chest pain—Doxorubicin—kidney cancer	4.39e-05	0.000178	CcSEcCtD
Rasagiline—Anxiety—Doxorubicin—kidney cancer	4.37e-05	0.000177	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	4.36e-05	0.000176	CcSEcCtD
Rasagiline—MAOB—Metabolism—SLC2A1—kidney cancer	4.36e-05	0.000357	CbGpPWpGaD
Rasagiline—Discomfort—Doxorubicin—kidney cancer	4.34e-05	0.000176	CcSEcCtD
Rasagiline—Dizziness—Capecitabine—kidney cancer	4.32e-05	0.000175	CcSEcCtD
Rasagiline—Dry mouth—Doxorubicin—kidney cancer	4.29e-05	0.000174	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—CYP1A1—kidney cancer	4.28e-05	0.000351	CbGpPWpGaD
Rasagiline—Confusional state—Doxorubicin—kidney cancer	4.24e-05	0.000172	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP1A1—kidney cancer	4.23e-05	0.000346	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—RAF1—kidney cancer	4.2e-05	0.000344	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—RELA—kidney cancer	4.18e-05	0.000343	CbGpPWpGaD
Rasagiline—Infection—Doxorubicin—kidney cancer	4.18e-05	0.000169	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—ERBB2—kidney cancer	4.15e-05	0.000341	CbGpPWpGaD
Rasagiline—Vomiting—Capecitabine—kidney cancer	4.15e-05	0.000168	CcSEcCtD
Rasagiline—BCL2—Immune System—CD8A—kidney cancer	4.15e-05	0.00034	CbGpPWpGaD
Rasagiline—Shock—Doxorubicin—kidney cancer	4.14e-05	0.000168	CcSEcCtD
Rasagiline—Nervous system disorder—Doxorubicin—kidney cancer	4.13e-05	0.000167	CcSEcCtD
Rasagiline—Rash—Capecitabine—kidney cancer	4.12e-05	0.000167	CcSEcCtD
Rasagiline—Dermatitis—Capecitabine—kidney cancer	4.11e-05	0.000166	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—MTOR—kidney cancer	4.1e-05	0.000336	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CD4—kidney cancer	4.09e-05	0.000335	CbGpPWpGaD
Rasagiline—Headache—Capecitabine—kidney cancer	4.09e-05	0.000166	CcSEcCtD
Rasagiline—Skin disorder—Doxorubicin—kidney cancer	4.09e-05	0.000165	CcSEcCtD
Rasagiline—Hyperhidrosis—Doxorubicin—kidney cancer	4.07e-05	0.000165	CcSEcCtD
Rasagiline—Anorexia—Doxorubicin—kidney cancer	4.01e-05	0.000162	CcSEcCtD
Rasagiline—Hypotension—Doxorubicin—kidney cancer	3.93e-05	0.000159	CcSEcCtD
Rasagiline—Nausea—Capecitabine—kidney cancer	3.88e-05	0.000157	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CDKN1B—kidney cancer	3.85e-05	0.000315	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Doxorubicin—kidney cancer	3.83e-05	0.000155	CcSEcCtD
Rasagiline—Insomnia—Doxorubicin—kidney cancer	3.81e-05	0.000154	CcSEcCtD
Rasagiline—Paraesthesia—Doxorubicin—kidney cancer	3.78e-05	0.000153	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—ACY1—kidney cancer	3.77e-05	0.000309	CbGpPWpGaD
Rasagiline—Dyspnoea—Doxorubicin—kidney cancer	3.75e-05	0.000152	CcSEcCtD
Rasagiline—Somnolence—Doxorubicin—kidney cancer	3.74e-05	0.000151	CcSEcCtD
Rasagiline—Dyspepsia—Doxorubicin—kidney cancer	3.7e-05	0.00015	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—JUN—kidney cancer	3.66e-05	0.0003	CbGpPWpGaD
Rasagiline—Decreased appetite—Doxorubicin—kidney cancer	3.66e-05	0.000148	CcSEcCtD
Rasagiline—MAOB—Metabolism—GSTP1—kidney cancer	3.63e-05	0.000298	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CTNNB1—kidney cancer	3.63e-05	0.000298	CbGpPWpGaD
Rasagiline—Gastrointestinal disorder—Doxorubicin—kidney cancer	3.63e-05	0.000147	CcSEcCtD
Rasagiline—Constipation—Doxorubicin—kidney cancer	3.6e-05	0.000146	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PTEN—kidney cancer	3.54e-05	0.00029	CbGpPWpGaD
Rasagiline—BCL2—Immune System—TSC2—kidney cancer	3.53e-05	0.000289	CbGpPWpGaD
Rasagiline—Feeling abnormal—Doxorubicin—kidney cancer	3.47e-05	0.00014	CcSEcCtD
Rasagiline—MAOB—Metabolism—ABCB1—kidney cancer	3.44e-05	0.000282	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Doxorubicin—kidney cancer	3.44e-05	0.000139	CcSEcCtD
Rasagiline—Urticaria—Doxorubicin—kidney cancer	3.34e-05	0.000135	CcSEcCtD
Rasagiline—MAOB—Metabolism—GSTM1—kidney cancer	3.34e-05	0.000274	CbGpPWpGaD
Rasagiline—Abdominal pain—Doxorubicin—kidney cancer	3.33e-05	0.000135	CcSEcCtD
Rasagiline—Body temperature increased—Doxorubicin—kidney cancer	3.33e-05	0.000135	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	3.21e-05	0.000263	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PDHB—kidney cancer	3.2e-05	0.000263	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—POMC—kidney cancer	3.19e-05	0.000262	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP1A1—kidney cancer	3.17e-05	0.00026	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KIT—kidney cancer	3.12e-05	0.000255	CbGpPWpGaD
Rasagiline—Hypersensitivity—Doxorubicin—kidney cancer	3.1e-05	0.000126	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—MAPK3—kidney cancer	3.03e-05	0.000248	CbGpPWpGaD
Rasagiline—Asthenia—Doxorubicin—kidney cancer	3.02e-05	0.000122	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—CCBL1—kidney cancer	3.01e-05	0.000247	CbGpPWpGaD
Rasagiline—Pruritus—Doxorubicin—kidney cancer	2.98e-05	0.000121	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—MAPK1—kidney cancer	2.88e-05	0.000236	CbGpPWpGaD
Rasagiline—Diarrhoea—Doxorubicin—kidney cancer	2.88e-05	0.000117	CcSEcCtD
Rasagiline—BCL2—Immune System—CDH1—kidney cancer	2.87e-05	0.000235	CbGpPWpGaD
Rasagiline—Dizziness—Doxorubicin—kidney cancer	2.78e-05	0.000113	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.72e-05	0.000223	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—KRAS—kidney cancer	2.72e-05	0.000223	CbGpPWpGaD
Rasagiline—Vomiting—Doxorubicin—kidney cancer	2.68e-05	0.000108	CcSEcCtD
Rasagiline—Rash—Doxorubicin—kidney cancer	2.65e-05	0.000107	CcSEcCtD
Rasagiline—Dermatitis—Doxorubicin—kidney cancer	2.65e-05	0.000107	CcSEcCtD
Rasagiline—Headache—Doxorubicin—kidney cancer	2.64e-05	0.000107	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—PPAT—kidney cancer	2.61e-05	0.000214	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GLIPR1—kidney cancer	2.61e-05	0.000214	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.58e-05	0.000211	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.55e-05	0.000209	CbGpPWpGaD
Rasagiline—Nausea—Doxorubicin—kidney cancer	2.5e-05	0.000101	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—PIK3CA—kidney cancer	2.5e-05	0.000205	CbGpPWpGaD
Rasagiline—BCL2—Immune System—RAF1—kidney cancer	2.45e-05	0.0002	CbGpPWpGaD
Rasagiline—BCL2—Immune System—RELA—kidney cancer	2.43e-05	0.0002	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—APRT—kidney cancer	2.43e-05	0.000199	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—FH—kidney cancer	2.43e-05	0.000199	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ERBB2—kidney cancer	2.42e-05	0.000198	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MTOR—kidney cancer	2.39e-05	0.000196	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD4—kidney cancer	2.38e-05	0.000195	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.37e-05	0.000195	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—POMC—kidney cancer	2.36e-05	0.000194	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GPC3—kidney cancer	2.28e-05	0.000187	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDKN1B—kidney cancer	2.24e-05	0.000184	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CA2—kidney cancer	2.22e-05	0.000182	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL2—kidney cancer	2.19e-05	0.00018	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ALAD—kidney cancer	2.16e-05	0.000177	CbGpPWpGaD
Rasagiline—BCL2—Immune System—JUN—kidney cancer	2.13e-05	0.000175	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CTNNB1—kidney cancer	2.12e-05	0.000174	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ST3GAL2—kidney cancer	2.11e-05	0.000173	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ALDH1A1—kidney cancer	2.07e-05	0.000169	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PTEN—kidney cancer	2.06e-05	0.000169	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PGK1—kidney cancer	1.98e-05	0.000162	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC5A3—kidney cancer	1.98e-05	0.000162	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—LDHB—kidney cancer	1.94e-05	0.000159	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTGS2—kidney cancer	1.88e-05	0.000154	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MAPK3—kidney cancer	1.76e-05	0.000145	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CA9—kidney cancer	1.68e-05	0.000138	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MAPK1—kidney cancer	1.68e-05	0.000138	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.65e-05	0.000135	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTEN—kidney cancer	1.64e-05	0.000135	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KRAS—kidney cancer	1.58e-05	0.00013	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CA—kidney cancer	1.46e-05	0.000119	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CRABP1—kidney cancer	1.43e-05	0.000117	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ITPR2—kidney cancer	1.33e-05	0.000109	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.23e-05	0.000101	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTT1—kidney cancer	1.21e-05	9.95e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ACHE—kidney cancer	1.21e-05	9.95e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CA—kidney cancer	1.16e-05	9.5e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SCARB1—kidney cancer	1.15e-05	9.42e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTGS1—kidney cancer	1.14e-05	9.32e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PSMD7—kidney cancer	1.12e-05	9.14e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—BCHE—kidney cancer	1.06e-05	8.67e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC5A5—kidney cancer	1.04e-05	8.56e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC2A1—kidney cancer	1.01e-05	8.27e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	9.79e-06	8.02e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	8.53e-06	7e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTP1—kidney cancer	8.41e-06	6.9e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ABCB1—kidney cancer	7.96e-06	6.53e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTM1—kidney cancer	7.73e-06	6.34e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP1A1—kidney cancer	7.33e-06	6.01e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.02e-06	4.93e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—POMC—kidney cancer	5.46e-06	4.48e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTGS2—kidney cancer	4.36e-06	3.57e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTEN—kidney cancer	3.8e-06	3.12e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CA—kidney cancer	2.68e-06	2.2e-05	CbGpPWpGaD
